Detailed explanation of the domestic price and purchasing information of Avonib

Ivosidenib (Ivosidenib), as a targeted therapy drug for specific cancer types, mainly targets patients who carry isocitrate dehydrogenase1 (IDH1) gene mutations. IDH1Gene mutations are common in acute myeloid leukemia (AML) and some solid tumors. The mechanism of action of ivonib is to inhibit the activity of IDH1 enzyme, thereby blocking the abnormal metabolic pathways of cancer cells and effectively inhibiting the growth and spread of tumors.

At present, Avonib has been launched in China, but it has not yet been included in the medical insurance catalog. Therefore, its market price is relatively high, with the price of a box being about 30,000 to 40,000 yuan. The specific selling price may vary depending on the region and sales channel. It is recommended to consult a local hospital or regular pharmacy to obtain the accurate price. In comparison, the price of generic drugs in foreign markets, especially in Laos, is relatively affordable, about six to seven thousand yuan, and the drug ingredients are basically the same as the original drugs.

Avosidenib is mainly suitable for patients with acute myeloid leukemia with IDH1 mutations, especially those who are not suitable for conventional chemotherapy or who are resistant to conventional treatment. In addition, it has shown potential in the exploratory treatment of other cancers such as relapsed or refractory cholangiocarcinoma.

This drug is usually an oral preparation, and patients need to take it on time every day to ensure that the drug continues to work in the body. The drug is mainly metabolized by the liver, so patients with hepatic impairment should use it with special caution. Common side effects include fatigue, nausea, diarrhea, joint pain, and a decrease in white blood cells. Because ivonib may cause serious side effects such as differentiation syndrome and prolongation of the QT interval, patients need to receive regular medical monitoring during treatment.

The launch of ivonib brings new treatment hope to cancer patients carrying IDH1 mutations, especially those for whom traditional treatments are ineffective. However, in view of its high price and individual differences in treatment effects, patients should have in-depth communication with their doctor before choosing to use it to determine whether the drug is suitable for their own treatment plan.